Controversy over the pharmacological treatments of storage symptoms in spinal cord injury patients: A literature overview

Spinal Cord

Volumn 50, Issue 1, 2012, Pages 8-13

  Del Popolo, G ^a   Mencarini, M ^a   Nelli, F ^a   Lazzeri, M ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

antimuscarinics; drugs; spinal cord injury; urinary incontinence; vanilloids

Indexed keywords

ALCOHOL; BOTULINUM TOXIN A; CAPSAICIN; CATION CHANNEL; DARIFENACIN; DRUG VEHICLE; EPITHELIAL SODIUM CHANNEL; FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NOCICEPTIN; OXYBUTYNIN; PLACEBO; PROPIVERINE; RESINIFERATOXIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE; VANILLOID RECEPTOR;

AUTONOMIC DYSREFLEXIA; BLADDER CAPACITY; BURNING SENSATION; CHRONIC DISEASE; DETRUSOR MUSCLE; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HEMATURIA; HUMAN; LOWER URINARY TRACT SYMPTOM; MICTURITION REFLEX; MUSCLE WEAKNESS; NERVE BLOCK; NEUROGENIC BLADDER; NEUROMODULATION; OVERACTIVE BLADDER; PAIN; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; REVIEW; SENSORY NERVE; SINGLE DRUG DOSE; SPINAL CORD INJURY; TREATMENT OUTCOME; URINE INCONTINENCE;

DRUG DESIGN; HUMANS; MUSCARINIC ANTAGONISTS; SPINAL CORD INJURIES; URINARY BLADDER, NEUROGENIC;

EID: 84857034502     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sc.2011.110     Document Type: Review

References (47)

1. Go BK, DeVivo MJ, Richards JS. The epidemiology of spinal cord injury. In: Stover SI, DeLisa JA, Whiteneck GC (eds). Spinal Cord Injury: Clinical Outcomes from the Model Systems. Aspen Publishers: Gaithersburg, 1995, pp 21-51.
2. Andersson KE. Antimuscarinics mechanisms and the overactive detrusor: an update. Eur Urol 2011; 59: 377-9.
3. Blok BFM, Willemsen TM, Holstege G. A PET study on brain control of micturition in humans. Brain 1997; 120: 111-112.
4. Kuhtz-Buschbeck JP, Van Der Horst C, Pott C, Wolff S, Nabavi A, Jansen O et al. Cortical representation of the urge to void: a functional magnetic resonance imaging study. J Urol 2005; 174: 1477-1481. (Pubitemid 41318769)
5. Maggi CA, Meli A. The sensory efferent function of capsaicin-sensitive neurons. Gen Pharmac 1988; 19: 1-43. (Pubitemid 18012850)
6. Maggi CA, Meli A. The role of neuropeptides in the regulation of micturition reflex. J Auton Pharmacol 1986; 6: 133-162. (Pubitemid 16079831)
7. Lazzeri M, Spinelli M. The challenge of overactive bladder therapy: alternative to antimuscarinic agents. Int Braz J Urol 2006; 32: 620-630. (Pubitemid 46138838)
8. Birder L. Role of the urothelium in bladder function. Scand J Urol Nephrol Suppl 2004; 215: 48.
9. de Groat WC, Kawatani M, Hisamitsu T, Cheng CL, Ma CP, Thor K et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 1990; 30(Suppl): 571-577.
10. Stöhrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009; 56: 81-88.
11. Stöhrer M, Murtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ. Propiverine compared to oxybutynin in neurogenic detrusor overactivity-results of a randomized, double blind, multicenter clinical study. Eur Urol 2007; 51: 235-242. (Pubitemid 44821506)
12. Reddy PP, Borgstein NG, Nijman RJM, Ellsworth PI. Longterm efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. J Pediatr Urol 2008; 4: 428-433.
13. Novartis Pharmaceuticals Corporation. Darifenacin phase III studies. Data on file (Summary of Clinical Efficacy, EMEA version May 2003, sections 2, 7, 3, 2, 7, 4 2, 7, 3 and 2, 7, 4).
14. Madersbacher H, Mü rtz G, Alloussi S, Domurath B, Henne T, Körner I et al. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. BJU Int 2009; 103: 776-781.
15. Stöhrer M, Bauer P, Giannetti BM, Richter R, Burgdö rfer H, Mü rtz G. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo controller double-blind trial. Urol Int 1991; 47: 138-143.
16. Kennelly MJ, Lemack GE, Foote JE, Trop CS. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology 2009; 74: 741-745.
17. Van Meel TD, De Wachter S, Wyndaele JJ. The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity. Neurourol Urodyn 2010; 29: 391-394.
18. Amend B, Hennenlotter J, Schäfer, Horstmann M, Stenzl A, Sievert KD. Effective treatment of neurogenic detrusor dysfunction by combined high-dose antimuscarinics without increased side-effects. Eur Urol 2008; 53: 1021-1028.
19. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692-697. (Pubitemid 30637604)
20. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K et al. Botulinum toxin A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174: 196-200. (Pubitemid 40825713)
21. Reitz A, Stohrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510-515. (Pubitemid 38376219)
22. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977-983.
23. Roosen A, Datta SN, Chowdhury RA, Patel PM, Kalsi V, Elneil S et al. Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment. Eur Urol 2009; 55: 1440-1448.
24. Patel AK, Patterson JM, Chapple CR. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol 2006; 50: 684-709.
25. Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006; 49: 528-535. (Pubitemid 43259564)
26. Del Popolo G, Filocamo MT, Li Marzi V, Macchiarella A, Cecconi F, Lombardi G et al. Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur Urol 2008; 53: 1013-1020. (Pubitemid 351434489)
27. Lazzeri M. Botulinum toxin A and lower urinary tract symptoms: non multa, sed multum (not many, but much). Eur Urol 2009; 55: 59-61.
28. De Ridder D, Chandiramani V, Dasgupta P, Van Poppel H, Baert L, Fowler CJ. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow-up. J Urol 1997; 158: 2087-2092. (Pubitemid 27481333)
29. Lazzeri M, Spinelli M, Beneforti P, Zanollo A, Turini D. Urodynamic assessment during intravesical instillation of capsaicin for the treatment of refractory detrusor hyperreflexia. Spinal Cord 1999; 37: 440-443. (Pubitemid 29317471)
30. Petersen T, Nielsen JB, Schroder HD. Intravesical capsaicin in patients with detrusor hyperreflexia: a placebo-controlled cross-over study. Scand J Urol Nephron 1999; 33: 104-110. (Pubitemid 29349806)
31. Lazzeri M, Spinelli M, Zanollo A, Turini D. Intravesical vanilloids and neurogenic incontinence: ten years experience. Urol Int 2004; 72: 145-149. (Pubitemid 38223800)
32. de Seze M, Wiart L, de Seze MP, Soyeur L, Dosque JP, Blajezewski S et al. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol 2004; 171: 251-255. (Pubitemid 37549136)
33. Lazzeri M, Beneforti P, Turini D. Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. J Urol 1997; 158: 2093-6. (Pubitemid 27481334)
34. Lazzeri M, Spinelli M, Beneforti P, Zanollo A, Turini D. resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases. Scand J Urol Nephrol 1998; 32: 331-334. (Pubitemid 28494068)
35. Giannantoni A, Di Stasi SM, Stephen RL, Navarra P, Scivoletto G, Mearini E et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 2002; 167: 1710-1714. (Pubitemid 34240708)
36. Peng CH, Kuo HC. Multiple intravesical instillations of low-dose resiniferatoxin in the treatment of refractory interstitial cystitis. Urol Int 2007; 78: 78-81.
37. Lazzeri M, Calò G, Spinelli M, Guerrini R, Beneforti P, Sandri S et al. Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study. J Urol 2001; 166: 2237-2240. (Pubitemid 33065264)
38. Lazzeri M, Calò G, Spinelli M, Guerrini R, Salvadori S, Beneforti P et al. Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. Urology 2003; 61: 946-950. (Pubitemid 36547736)
39. Lazzeri M, Calo G, Spinelli M, Malaguti S, Guerrini R, Salvadori S et al. Daily intravesical instillation of 1mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study. J Urol 2006; 176: 2098-2102. (Pubitemid 44633163)
40. Malaguti S, Spinelli M, Citeri M, Lazzeri M. Nociceptin/Orphanin FQ (N/OFQ) modulates the bladder pain in humans. Neurophysiological evidence by nociceptive flexion (RIII) reflex analysis. Eur Urol (Suppl) 2007; 6: 167.
41. Kellenberger S, Schild L. Epithelial sodium channel/degenerin family of ion channels: a variety of functions for a shared structure. Physiol Rev 2002; 82: 735-767. (Pubitemid 34743337)
42. Du S, Araki I, Mikami Y, Zakoji H, Beppu M, Yoshiyama M et al Amiloride-sensitive ion channels in urinary bladder epithelium involved in mechanosensory transduction by modulating stretch-evoked adenosine triphosphate release. Urology 2007; 69: 590-595. (Pubitemid 46428413)
43. Ferguson DR, Kennedy I, Burton TJ. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes-a possible sensory mechanism? J Physiol 1997; 505: 503-511. (Pubitemid 28043392)
44. Kellenberger S, Schild L. Epithelial sodium channel/degenerin family of ion channels: a variety of functions for a shared structure. Physiol Rev 2002; 82: 735-767. (Pubitemid 34743337)
45. Wemmie JA, Price MP, Welsh MJ. Acid-sensing ion channels: advances, questions and therapeutic opportunities. Trends Neurosci 2006; 29: 578-586. (Pubitemid 44416458)
46. Kobayashi H, Yoshiyama M, Zakoji H, Takeda M, Araki I. Sex differences in expression profile of acid-sensing ion channels in the mouse urinary bladder: a possible involvement in irritative bladder symptoms. BJU Int 2009; 104: 1746-1751.
47. Corrow K, Girard BM, Vizzard MA. Expression and response of acid-sensing ion channels (ASICs) in urinary bladder to cyclophosphamide (CYP)-induced cystitis. Am J Physiol Renal Physiol 2010; 298: F1130-F1139.